NCT01415102View on ClinicalTrials.gov

A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Phase 1Single DoseSafetyTolerationPharmacokinetics
Interventions
DRUG

PF-05212372

Inhaled. Dose Level 1: 50 ug

DRUG

PF-05212372

Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose

DRUG

PF-05212372

Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose

DRUG

PF-05212372

Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose

DRUG

Placebo

Inhaled

DRUG

PF-05212372

Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose

DRUG

PF-05212372

Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose

DRUG

PF-05212372

Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose

DRUG

Placebo

Inhaled

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY